Cipla
Cipla Ltd.
Mumbai Central
Mumbai 400 008

29th May 2013

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemberg

Dear Sirs,

Please find enclosed copy of Press Release dated 29th May, 2013.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Cipla
Caring for Life


Press Release


Cipla announces Q4 FY 1213 Unaudited Financial Results


Mumbai, India, 29th May 2013: Cipla Limited (BSE: 500087, NSE : CIPLA) today announced its Unaudited Financial Results for the quarter ended March 31, 2013 (Q4).


Key Financial & Performance Highlights Q4 FY1213 vis-a-vis Q4 FY1112:

- Gross revenues grew by 4.9% to ₹1982 cr, up from ₹1890 cr in Q4 FY1112
- Operating margins grew by 2.7% to ₹409 cr, up from ₹399 cr in Q4 FY1112
- Profit after tax fell by 8.3% to ₹268 cr, down from ₹292 cr in Q4 FY1112









Profit & Loss Highlights:

- Material cost at 38.7% of Total Sales decreased by 3.3% during Q4 FY1213 as compared to Q4 FY1112.
- Operating margins increased by 2.7% and is at 20.7% of Income from Operations during Q4 FY1213.
- Profit after tax decreased by 8.3% to ₹268 cr during Q4 FY1213 as compared to ₹292 cr during Q4 FY1112.

Performance Review:

Domestic business:

- Domestic revenues grew by 5.2% to ₹793 cr during Q4 FY1213, up from ₹754 cr during Q4 FY1112.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments.

International business:

- Exports of formulations grew by 11.5% to ₹954 cr during Q4 FY1213, up from ₹855 cr during Q4 FY1112.
- Exports of APIs fell by 24.0% to ₹175 cr during Q4 FY1213, from ₹230 cr during Q4 FY1112.
- The growth in export revenues was primarily due to growth in anti-asthma, anti-allergic, anti-depressants, and anti-retroviral segments.

About Cipla:
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US$ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

Media Contact:

Finance
Ajay Luharuka
Contact No.: 022 – 23025435
E-Mail: ajay@cipla.com

Corporate Communications
Jaisingh Balakrishnan
Contact No.: 022 - 23025813
E Mail: jaisingh.krishnan@cipla.com